Abstract：
Transcriptomics was used to investigate the mechanism of action of Bushen Culuan Formula in the treatment of infertility caused by hyperprolactinemia(HPRL), and animal experiments were carried out to verify the results. After establishing an animal model of HPRL-induced infertility, the mice were divided into normal group, model group, Bushen Culuan Formula groups with high-, medium-, and low-doses, and bromocriptine group, and they were observed in terms of the estrous cycle, gonadal index, serum sex hormones, morphology of ovary and mammary gland, follicle count, and fertility. The results showed that the Bushen Culuan Formula could effectively restore the estrous cycle, down-regulate the levels of prolactin(PRL), follicle-stimulating hormone(FSH), and luteinizing hormone(LH), up-regulate the level of estradiol(E_2), increase the number of primordial follicles and sinus follicles, and improve the ovulation rate and fertility of mice. Through RNA sequencing combined with biosignature analysis, Bushen Culuan Formula may regulate the metabolism of lipids, antioxidant enzymes, and other substances in the cells of the ovary and pituitary gland through the signaling pathways of cAMP-PKA, Kiss-1/GPR54, and Hippo and exert therapeutic effects. The results of animal experiments showed that Bushen Culuan Formula could up-regulate serum dopamine(DA) level and pituitary DRD2 expression, down-regulate hypothalamus and ovary cAMP levels, as well as protein expressions of the pituitary gland and ovary PKA, CREB, and p-CREB, and treat HPRL-induced infertility by regulating the cAMP-PKA signaling pathway.
摘要：
采用转录组学方法探讨补肾祛胆方治疗高催乳素血症(HPRL)所致不孕症的作用机制,并进行动物实验验证结果。建立HPRL诱导的不孕症动物模型后,将小鼠分为正常组，模型组,补肾库伦公式组配高,medium-,和低剂量，和溴隐亭组，它们是根据发情周期观察到的，性腺指数,血清性激素,卵巢和乳腺的形态，卵泡计数,和生育能力。结果表明,补肾库伦配方能有效恢复发情周期,下调催乳素（PRL）的水平，卵泡刺激素（FSH），和黄体生成素（LH），上调雌二醇(E_2)水平，增加原始卵泡和窦卵泡的数量，提高小鼠的排卵率和生育能力。通过RNA测序结合生物特征分析，补肾祛微方可能调节血脂代谢,抗氧化酶，和卵巢和垂体细胞中的其他物质通过cAMP-PKA的信号通路，亲吻-1/GPR54，和河马，发挥治疗作用。动物实验结果表明,补肾祛微方能上调血清多巴胺(DA)水平和垂体DRD2的表达,下调下丘脑和卵巢cAMP水平，以及垂体和卵巢PKA的蛋白表达,CREB,和p-CREB,并通过调节cAMP-PKA信号通路治疗HPRL引起的不孕症。
